Quantcast

Latest Quinazolines Stories

2008-07-08 12:00:16

The medical advisory panel to the UK National Health Service has recommended that GlaxoSmithKline's Tyverb should not be used on the NHS to treat advanced metastatic breast cancer on the grounds that it is not effective enough to justify its cost. This decision represents not only a blow to GSK but also casts doubt on how many other new cancer therapies will be available in the UK. The UK panel ruled that, based on data showing that the median survival time for women who received Tyverb...

2008-07-08 09:01:10

By Barry Nelson A FATHER-OF-THREE who was trying to raise [pounds]20,000 to buy a new cancer drug has died at home surrounded by family. Colin Glease, 45, from Dipton, near Stanley, County Durham, died on Saturday from advanced pancreatic cancer. Since he was diagnosed with cancer a year ago, Mr Glease endured repeated bouts of chemotherapy at hospital in Durham City. His hopes were raised recently when he was enrolled on an experimental drug trial, but he failed to respond to...

2008-07-08 09:00:12

The National Institute of Health and Clinical Excellence has advised against the use of GlaxoSmithKline's oral cancer drug Tyverb in the UK's National Health Service, reported the Financial Times. According to the Financial Times, The National Institute of Health and Clinical Excellence (NICE) has issued a provisional recommendation that Tyverb for advanced breast cancer failed to meet its threshold for clinical and cost effectiveness. GSK tried to negotiate a 'risk-sharing' arrangement...

2008-07-07 09:00:16

* Alocrest(tm) Phase 1 Data Demonstrates Potential for Improved Safety and Efficacy Compared to Conventional Vinorelbine * Menadione Topical Lotion Restores Kinase Activity and Does Not Inhibit the Anti-Tumor Effect of Erlotinib (Tarceva(r)) in Preclinical Models SOUTH SAN FRANCISCO, Calif., July 7, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, presented data for two of the...

2008-06-25 06:00:56

By Claire Harrison Dr Seamus McAleer has been involved in trials of a new drug called Lapatinib at Belfast City Hospital which has offered women suffering a type of advanced breast cancer hope by slowing the disease. Around 1,000 women are diagnosed with breast cancer in Northern Ireland every year, with a quarter suffering the aggressive, fast- growing ErbB2-positive kind of the disease. For many women with this form of the disease who initially respond to treatment with Herceptin and...

2008-06-14 00:00:31

KIM Robson pounded the streets of Leeds in Jane Tomlinson's Run for All last year and will line up with thousands of others against for the event next week. She began running to keep fit only two years ago but soon after taking part in a fun run for cancer research, her world was turned upside down when she found a lump in her breast. Her GP in Ilkley referred her for tests which confirmed she had cancer. She underwent chemotherapy and then had major surgery on a fast- growing...

2008-06-14 00:00:07

NEW drug lapatinib is described as a "stealth fighter" against breast cancer. It is not a cure but temporarily stops progression of the disease for women with advanced cases of breast cancer who test positive for the protein HER2. Maker GlaxoSmithKline estimates its drug will help 2,000 women a year in the UK. These are patients who have been treated using other frontline therapies including surgery, chemotherapy and radiotherapy and whose disease has stopped responding to another drug,...

2008-03-05 09:01:06

Response Genetics, Inc. (NASDAQ: RGDX) announced today that its ResponseDX: Lung™ and ResponseDX: Colon™ tests are now available to select medical institutions and practice groups through its CLIA-registered laboratory. ResponseDX: Lung™ and ResponseDX: Colon™ are PCR-based tests that help guide therapeutic treatment decisions in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The tests are in their initial launch phase and are...

2006-06-05 13:15:42

LOS ANGELES (Reuters) - A mid-stage trial suggests that a combination of cancer drugs Avastin and Tarceva can prolong survival in patients with advanced lung cancer, compared with chemotherapy alone, drug makers Genentech Inc. and OSI Pharmaceuticals said on Monday Avastin, made by Genentech, is the first cancer drug designed to work by cutting off blood supply to tumors. Tarceva, a product of Genentech and OSI, is an oral drug designed to target the human epidermal growth factor...

2006-06-05 07:40:00

By Toni Clarke ATLANTA (Reuters) - Using combinations of "smart bomb" cancer drugs that target specific proteins and avoid the indiscriminate cell destruction of chemotherapy may be the wave of the future for cancer patients, experts say. Early studies show that combining targeted treatments such as Genentech Inc.'s breast cancer drug Herceptin with GlaxoSmithKline Plc's experimental treatment Tykerb, may be helpful in patients who do not respond to Herceptin alone, said Dr. Jose Baselga,...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related